Grifols Therapeutics Inc.

Grifols, S.a.

Syngenta Participations Ag

Talecris Biotherapeutics, Inc.

Jennifer Audrey Hunt

Thomas P Zimmerman

Valery Novokhatny

Charles Miller

David Ownby

Senthil Ranganathan

Tonny Dessources

Stephen Robert Petteway

James Rebbeor

Edward Koepf

Paul Bernasconi

Kimberly Ann White

Philip Scuderi, Jr

Robert Michael Petrovich

Gary Keith Powell

Myles Lindsay

Ray Donald Carpenter

Rebecca Silverstein

Anthony Caronna

Kenya Stokes

Vikram Arora

Tony Dessources

Described herein are methods for purifying recombinant, cell culture derived alpha-protease inhibitor and removing a colored species that co-purifies with the recA1PI protein. Also described are methods for reducing the iron in cell culture derived alpha-protease inhibitor.

Purification of cell culture derived alpha1 protease inhibitor

[object Object]

Compositions and methods for preparing plasminogen, in particular recombinant plasminogen, and compositions and methods of utilizing same for preparing plasmin are provided.

Compositions, methods and kits for preparing plasminogen and plasmin prepared therefrom

Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.

Recombinantly modified plasmin

Methods of using polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided, including methods related to vitrectomy or vitreolysis. The plasmin(ogen) molecule has a single kringel domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.

Recombinant plasmin for opthalmic indications

A parallel high throughput method and kit for the discovery of small molecule interactors of target proteins, in particular, target proteins expressed from entire genomes or subsets thereof. The target module is prepared by binding selectively a target protein, modified to allow its detection, to a surrogate ligand that is linked to an individually detectable bead. Sets of target modules are mixed together in each chamber of a multi-chamber container. A test compound or collection of test compounds is added to each chamber, and the interaction of a compound with each target module is observed. A compound that is specific for a particular target protein will displace that protein from its target module. The identity of the target module so disrupted is determined by identifying the particular bead to which the displaced target protein was attached.

Parallel high throughput method and kit

Growing community of inventors

Raleigh, NC, United States of America

Jennifer Audrey Hunt